RxDoctor Payments Data

Andrew Tobkes, MD

Gastroenterology · Rockledge, FLNPI 1215920475

Payments from drug & device makers

$4,156in general payments, 2019–2025

Across 214 payments — averaging $19.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$661
  • Merck$286
  • Takeda Pharmaceuticals U.S.A., Inc.$241
  • Bristol Myers Squibb$237
  • Phathom Pharmaceuticals, Inc.$226
  • plus $1K from 17 others

What the payments were for

  • Consulting fees$251%
  • Food & beverage$4,10899%
  • Education$221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,156 in reported general payments places this provider in the 50th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$284,654
Medicare patients
500
Services billed
7,183

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase13$60,285
LinzessLinaclotide43$36,605
Mesalamine29$12,710
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates160$10,233
Omeprazole251$5,685
Mesalamine ErMesalamine12$4,097
KonvomepOmeprazole/Sodium Bicarbonate12$3,984
Pantoprazole Sodium194$3,618
CholestyramineCholestyramine (With Sugar)36$3,307
SutabSod Sulf/Pot Chloride/Mag Sulf12$1,967
Lubiprostone12$1,783
Colestipol Hcl15$1,265
Famotidine62$1,251
Ondansetron OdtOndansetron19$1,004
Tenofovir Disoproxil Fumarate11$659

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,468$96,89156 claims
Braintree Laboratories, Inc.Sutab$135$1,96712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Rockledge

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →